HealthDay Now: Experts Weigh In On Alzheimer's Drug Controversy

In a HealthDay Now interview, Mabel Jong heard from experts with inside knowledge on the FDA's controversial approval of aducanumab. First up is Dr. G. Caleb Alexander, a professor at Johns Hopkins who served on the FDA advisory committee that nearly unanimously advised against approving Biogen's controversial new Alzheimer's drug. Then, a conversation between Dr. Anton Porsteinsson, a principal investigator for the drug trial, and Dr. Ken Lin, a primary care physician who, like most clinicians surveyed in a new poll, has his concerns and has said he will not prescribe the new drug.

Categories: For Potential Participants, [Cancer, Psychosis, Arthritis, Rheumatoid Arthritis, Breast Cancer, Stroke, Surgery, Eating Disorders, Depression, Heart Failure, Autism, ADHD, Diabetes, Lupus, Smoking, Osteoporosis, Headache, Migraine]


healthdaylogo

Copyright © 2021 HealthDay. All rights reserved.


Related Articles

For Potential Participants

Results of ClinicalResearch.com community survey for 2018

We surveyed our users at the end of 2018 and here is what we learned!

For Potential Participants

Could a vaccine be used to help prevent type 1 diabetes?

Finnish clinical trials to study enterovirus vaccine, to see if it may help prevent type 1 diabetes

For Potential Participants

Researchers believe there may be 5 types of diabetes

Could a more personalized treatment plan be needed?

Want more information about clinical trials near you?

Register to get notifications about clinical trials in your area.
Register to Receive Updates